The IGF2BP3 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, designed for loss-of-function studies of the IGF2BP3 gene. This polyclonal pool is generated via CRISPR/Cas9-mediated gene disruption, producing a heterogeneous knockout model suitable for investigating IGF2BP3-dependent oncogenic processes while retaining genetic diversity.
HeLa is an immortalized human cell line from cervical adenocarcinoma, widely used in cervical cancer research due to its rapid growth and well-characterized signaling abnormalities. Its permissiveness to genetic manipulation and faithful recapitulation of tumor cell behaviors, such as migration and invasion, make it an ideal background for studying oncogenic factors like IGF2BP3.
IGF2BP3 is an RNA-binding protein that stabilizes oncogenic mRNAs by binding to their 3?? UTRs, enhancing translation and preventing degradation. In HeLa cells, IGF2BP3 overexpression drives proliferation, migration, and invasion through upregulation of c-MYC and CD44. IGF2BP3 is transcriptionally regulated by ??-catenin, c-MYC, SOX2, and LIN28, and it stabilizes targets including c-MYC, CD44, IGF2, HMGA2, and CCND1 mRNAs. It interacts with HuR, LIN28A, IMP1, eIF4E, and matrin 3, integrating Wnt/??-catenin, MAPK/ERK, PI3K/AKT, and TGF-??/Smad signaling pathways with representative components such as TCF4, ERK1/2, AKT, and SMAD2/3. Through these interactions, IGF2BP3 exerts control over cell cycle progression and invasive capacity.
In the HeLa cervical adenocarcinoma background, IGF2BP3 is critical for maintaining malignant phenotypes by sustaining target mRNA expression. Disruption of IGF2BP3 in this polyclonal knockout population impairs its post-transcriptional network, reducing proliferation and metastatic potential. This model enables the study of cervical cancer cell dependency on IGF2BP3-mediated mRNA stabilization and the exploration of clonal heterogeneity in response to perturbations. This system also permits the investigation of potential therapeutic strategies targeting the IGF2BP3 regulatory axis.
This model supports diverse applications in cancer biology, mRNA stability and translation regulation, oncogene addiction, and drug target validation. Representative assays include Western blotting, RT-qPCR for mRNA half-life, migration/invasion (Boyden chamber), proliferation (MTT/CCK-8), RNA immunoprecipitation, reporter assays, and immunofluorescence. Researchers can employ this model to screen small-molecule inhibitors or RNA-based therapeutics that disrupt IGF2BP3-mRNA interactions. For technical support and ordering details, contact Ascent Research.
